Cardiology Division, Massachusetts General Hospital, Boston, MA.
Harvard Medical School, Boston, MA.
Clin Chem. 2018 Nov;64(11):1617-1625. doi: 10.1373/clinchem.2017.286385. Epub 2018 Sep 13.
Endothelin-1 (ET-1) is a vasoconstrictor produced by vascular endothelial cells and may play a role in risk for development of coronary artery disease (CAD) and heart failure (HF). In a cohort of 1084 patients referred for coronary angiography, we investigated cross-sectional associations between ET-1 concentrations and prevalent CAD, as well as value of ET-1 for prognostication of future cardiovascular events.
Associations between ET-1 and presence/severity of CAD were assessed. Patients were followed for a median of 4 years for outcomes including incident HF, myocardial infarction (MI), cardiovascular mortality, and all-cause mortality.
The median concentration of ET-1 was 2.57 ng/L. Patients with ET-1 concentrations above the median were more likely to have higher risk clinical features. Among those without prevalent MI at presentation, ET-1 concentrations were not associated with presence or severity of CAD. In adjusted Cox proportional hazards analyses, log-transformed ET-1 concentrations predicted incident HF [hazard ratio (HR) = 1.51 per increase in log-SD; 95% CI, 1.06-2.15; = 0.02] and all-cause mortality (HR = 1.61 per increase in log-SD; 95% CI, 1.03-2.53; = 0.04). Concentrations of ET-1 above the median were associated with shorter time to incident HF, MI, cardiovascular mortality, all-cause mortality, and the composite of incident HF/MI/cardiovascular mortality (all log-rank < 0.001).
Despite epidemiologic links to CAD, we found no cross-sectional association between biologically active ET-1 and prevalent coronary atherosclerosis in an at-risk population referred for coronary angiography. Increased ET-1 concentrations independently predict incident HF and death and are associated with more near-term cardiovascular events.
内皮素-1(ET-1)是血管内皮细胞产生的血管收缩剂,可能在冠状动脉疾病(CAD)和心力衰竭(HF)的发病风险中发挥作用。在一项对 1084 例接受冠状动脉造影检查的患者的队列研究中,我们研究了 ET-1 浓度与现有 CAD 之间的横断面关联,以及 ET-1 对预测未来心血管事件预后的价值。
评估 ET-1 与 CAD 存在/严重程度之间的关系。患者中位随访 4 年,以评估新发 HF、心肌梗死(MI)、心血管死亡率和全因死亡率等结局。
ET-1 的中位数浓度为 2.57ng/L。ET-1 浓度高于中位数的患者更有可能具有更高的风险临床特征。在那些初诊时没有 MI 的患者中,ET-1 浓度与 CAD 的存在或严重程度无关。在调整后的 Cox 比例风险分析中,对数转换的 ET-1 浓度预测新发 HF [危险比(HR)=每增加 log-SD 1.51;95%CI,1.06-2.15;P=0.02]和全因死亡率(HR=每增加 log-SD 1.61;95%CI,1.03-2.53;P=0.04)。ET-1 浓度高于中位数与新发 HF、MI、心血管死亡率、全因死亡率以及 HF/MI/心血管死亡率的复合终点(所有 log-rank P<0.001)的发生时间更短有关。
尽管与 CAD 存在流行病学联系,但在高危人群中,我们在接受冠状动脉造影检查的患者中没有发现生物活性 ET-1 与现有冠状动脉粥样硬化之间的横断面关联。升高的 ET-1 浓度独立预测新发 HF 和死亡,并与更近期的心血管事件相关。